BlueOcean NutraSciences Inc.
TSX VENTURE : BOC

BlueOcean NutraSciences Inc.

September 01, 2015 11:25 ET

BlueOcean NutraSciences Pure Polar™ Products and Web Site Launched

TORONTO, ONTARIO--(Marketwired - Sept. 1, 2015) - BlueOcean NutraSciences (TSX VENTURE:BOC) ("BlueOcean" or the "Company"), a nutraceutical Company focused on developing specialty oils and extended release (XR) Omega3 oil tablets from shrimp, fish, krill and algae oil for Health and Wellness markets, is pleased to announce that its new line of Pure Polar™ dietary supplements are now available for pre-ordering on line with product delivery within 30 days. The Company's Pure Polar XR™ Omega 3 tablet product was recently Named Among Top CPG Products for Innovation and Market Impact is available for a limited time at a low introductory price.

BlueOcean's PurePolar™ shrimp oil products are the world's first Omega-3 oil products from shrimp with 10 times the red (astaxanthin) of comparable krill oil products. Product details and ordering information at:

www.purepolarshrimp.com

About BlueOcean NutraSciences Inc.

BlueOcean NutraSciences Inc. is a Canadian listed public Company (TSX VENTURE:BOC) that is focused on developing sustainable, specialty nutraceutical oil products targeted at the rapidly growing Natural Astaxanthin, Omega-3 and Algal oil health and wellness markets.

BlueOcean and its JV partner, CMAX technologies, have developed a process to convert shrimp, krill, algae and other fish oils into Extended Release Tablets. BlueOcean owns 50% of the participating and voting rights in 2453969 Ontario Inc., a joint venture with CMAX Technologies that has developed the extended release omega-3/astaxanthin tablets.

The natural oils to be used in BlueOcean's products contain high levels of naturally occurring astaxanthin, phospholipids, and omega-3 EPA and DHA. AstaShrimp™ are targeted at the high value and rapidly growing natural astaxanthin market. AlgaOmega™ oil is vegetarian, non-GMO omega-3 algal oil containing high levels of EPA with Polar Lipids and is targeted at the rapidly growing omega-3 algal oil ingredient market. The extended release tablets target the rapidly growing omega-3 consumer market and astaxanthin consumer dietary supplements markets.

Forward Looking Statements: BlueOcean

This news release may contain forward-looking statements that are based on BlueOcean's expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • BlueOcean NutraSciences Inc.
    Gavin Bogle
    CEO
    416-970-3266

    BlueOcean NutraSciences Inc.
    Dil Vashi
    Director of Corporate Development
    416-859-0909
    www.blueoceannutra.ca